


IN THE CLAIMS


Please cancel claims 1-27 and add the following new claims.

28. (New) A nitrogen heterocyclic aromatic derivative having the following general formula:




where X and Y are selected from N, C and CH, provided they are different from each other, or X and Y are both nitrogen;

B₁
R is hydrogen or -COR₈ where R₈ is a saturated or non-saturated C₁-C₁₀ aliphatic hydrocarbon, R₁ has the following general formula:




where R₃ is hydrogen, halogen, C₁-C₁₀ alkyl or C₁-C₁₀ alkoxy, R₄ is hydrogen, C₁-C₁₀ alkyl or C₁-C₁₀ alkoxy, or R₃ and R₄ together form a methylenedioxy group;


R₂ has the following general structure:



and R₅ is selected from:



where Z=OR₇ where R₇ is a saturated or non-saturated, linear or branched C₁-C₁₀ aliphatic hydrocarbon, or R₇ has the following formula:




where R, R₁, X and Y are defined as above and R₆ is hydrogen, halogen, alkyl or alkoxy C₁-C₁₀, or Z is NHR₈ where R₈ is a linear or branched C₁-C₂₀ alkyl chain,

provided that when X=Y=N and R is H or -CONHCH₂CH₃, Z is not NHR₈ where R₈ is -CH₂CH₃, and provided that R₁ and R₂ are not located on two adjacent atoms of the heterocyclic aromatic ring, and further provided that when X=Y=N and R₅ is -COZ where Z=OR₇, R₇ is a saturated or non-saturated linear or branched C₅-C₂₀ aliphatic hydrocarbon.


29. (New) The nitrogen heterocyclic aromatic derivative according to claim 28 wherein when R₇ is a saturated or non-saturated C₁-C₂₀ aliphatic hydrocarbon it is a linear or branched alkyl, alkenyl or alkynyl which may contain one or more double or triple bonds.

3
30. (New) The nitrogen heterocyclic aromatic derivative according to claim 28 in which alkyl or alkoxy is a linear or branched C₁-C₁₀ alkyl or alkoxy group.

4
31. (New) The nitrogen heterocyclic aromatic derivative according to the claim 28 wherein the ring structure of formula (I) is:




or



5
32. (New) The nitrogen heterocyclic aromatic derivative according to claim 28




having the following general formula:




(IV)

where R₃ is hydrogen, halogen, C₁-C₁₀ alkyl or C₁-C₁₀ alkoxy, R₄ is hydrogen, C₁-C₁₀ alkyl or C₁-C₁₀ alkoxy, or R₃ and R₄ together form a methylenedioxy group,

R₅ is one of:



where Z=OR₇ where R₇ is a saturated or non-saturated, linear or branched C₁-C₂₀ aliphatic hydrocarbon, or is chosen from the following formula:



where R, R₁, X and Y are defined as above and R₆ is hydrogen, halogen, alkyl or alkoxy C₁-C₁₀, or Z is NHR₈ where R₈ is a linear or branched C₁-C₂₀ alkyl chain,


provided that when R₅ is -COZ where Z=OR₇, R₇ is a saturated or non-saturated, linear or branched C₅-C₁₀ aliphatic hydrocarbon.

33. (New) The nitrogen heterocyclic aromatic derivative according to claim 32,

wherein R₆ = hydrogen, R₄ = OCH₃ or OCH₂CH₃, R₃ is hydrogen, R₅ is COZ where Z=OR₇ where R₇ is a saturated linear aliphatic C₅-C₁₂ hydrocarbon.


34. (New) The nitrogen heterocyclic aromatic derivative according to claim 28

having the following structure:



35. (New) The nitrogen heterocyclic aromatic derivative according to claim 28


having the following structure:



9 — (XVI)


36. (New) The nitrogen heterocyclic aromatic derivative according to claim 28

having the following structure:



(XIII)

37. (New) Nitrogen heterocyclic aromatic derivative according to claim 28 having the following structure:



(XVII)

38. (New) A pharmaceutical composition comprising a nitrogen heterocyclic aromatic derivative according to claim 28 together with a pharmaceutically acceptable diluent or carrier.

39. (New) The pharmaceutical composition according to claim 37 in the form of a transdermal skin patch.

40. (New) The pharmaceutical composition according to claim 37 for intravenous administration.

41. (New) The pharmaceutical composition according to claim 38 wherein the diluent or carrier is a vegetable oil or an ester of fatty acid suitable for an epicutaneous, subcutaneous or intramuscular administration.

42. (New) The pharmaceutical composition according to claim 41 wherein the diluent is sesame oil, corn oil, peanut oil, cotton seed oil or ethyl oleate.

¹⁶
43. (New) The pharmaceutical composition according to claim ¹¹~~38~~ also including anti-microbial agent.

¹⁷
44. (New) The pharmaceutical composition according to claim ¹¹~~38~~ also including an anti-oxidative agent.

¹⁸
45. (New) The pharmaceutical composition according to claim ¹¹~~38~~ which contains from 1 to 10% (w/v) of the nitrogen heterocyclic aromatic derivative.

¹⁹
46. (New) A method of terminating pregnancy in a mammal comprising administering an effective amount of a nitrogen heterocyclic aromatic derivative of claim ¹~~28~~.

²⁰
47. (New) A method of reducing the humoral and cellular immunological response of a mammal comprising administering an effective amount of a nitrogen heterocyclic aromatic derivative of claim 28.

48. (New) A method of treating a tumor susceptible to therapy comprising administering an effective amount of a nitrogen heterocyclic aromatic derivative of claim 28.

Attached: Abstract of the Disclosure